Ophthalmology, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK.
Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
Br J Ophthalmol. 2022 Aug;106(8):1051-1056. doi: 10.1136/bjophthalmol-2020-318570. Epub 2021 Apr 26.
BACKGROUND /AIMS: To evaluate the performance of existing prediction models to determine risk of progression to referable diabetic retinopathy (RDR) using data from a prospective Irish cohort of people with type 2 diabetes (T2D).
A cohort of 939 people with T2D followed prospectively was used to test the performance of risk prediction models developed in Gloucester, UK, and Iceland. Observed risk of progression to RDR in the Irish cohort was compared with that derived from each of the prediction models evaluated. Receiver operating characteristic curves assessed models' performance.
The cohort was followed for a total of 2929 person years during which 2906 screening episodes occurred. Among 939 individuals followed, there were 40 referrals (4%) for diabetic maculopathy, pre-proliferative DR and proliferative DR. The original Gloucester model, which includes results of two consecutive retinal screenings; a model incorporating, in addition, systemic biomarkers (HbA1c and serum cholesterol); and a model including results of one retinopathy screening, HbA1c, total cholesterol and duration of diabetes, had acceptable discriminatory power (area under the curve (AUC) of 0.69, 0.76 and 0.77, respectively). The Icelandic model, which combined retinopathy grading, duration and type of diabetes, HbA1c and systolic blood pressure, performed very similarly (AUC of 0.74).
In an Irish cohort of people with T2D, the prediction models tested had an acceptable performance identifying those at risk of progression to RDR. These risk models would be useful in establishing more personalised screening intervals for people with T2D.
背景/目的:利用来自爱尔兰 2 型糖尿病(T2D)前瞻性队列的数据,评估现有预测模型在确定向可转诊的糖尿病视网膜病变(RDR)进展风险方面的性能。
使用前瞻性随访的 939 名 T2D 患者队列来测试英国格洛斯特和冰岛开发的风险预测模型的性能。将爱尔兰队列中观察到的进展为 RDR 的风险与从每个评估的预测模型中得出的风险进行比较。接收者操作特征曲线评估了模型的性能。
该队列共随访了 2929 人年,在此期间共进行了 2906 次筛查。在 939 名随访的个体中,有 40 人(4%)因糖尿病性黄斑病变、前增殖性 DR 和增殖性 DR 转诊。最初的格洛斯特模型包括两次连续视网膜筛查的结果;一个模型除了包含系统生物标志物(HbA1c 和血清胆固醇)外;另一个模型包含一次视网膜病变筛查、HbA1c、总胆固醇和糖尿病持续时间的结果,具有可接受的判别能力(曲线下面积(AUC)分别为 0.69、0.76 和 0.77)。冰岛模型结合了视网膜病变分级、糖尿病持续时间和类型、HbA1c 和收缩压,表现非常相似(AUC 为 0.74)。
在爱尔兰 T2D 患者队列中,测试的预测模型在识别有进展为 RDR 风险的患者方面具有可接受的性能。这些风险模型将有助于为 T2D 患者建立更个性化的筛查间隔。